| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |